OTC Markets OTCQB - Delayed Quote USD

NUREXONE BIOLOGIC INC (NRXBF)

0.4920

+0.0063

+(1.30%)

As of April 23 at 2:59:05 PM EDT. Market Open.

NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top

GlobeNewswire yesterday

NRXBF
+1.30%
NRXBF Enters Crucial Stage in Good Shape

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company, late last year, announced some preclinical test results that have the

Zacks Small Cap Research 14 days ago

NRXBF
+1.30%
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2024. The Company’s audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying management's discussion and analysis can be accessed by visiting the Company's web

GlobeNewswire 14 days ago

NRXBF
+1.30%
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 3,543,238 units (“Units”) at a price of C$0.65 per Unit for aggregate gross proceeds of C$2,303,105 (the “Offering”). The Company intends to use the proceeds of the Offering for working capital, ExoTop’s establishme

GlobeNewswire 20 days ago

NRXBF
+1.30%
NRXBF Test Results Bolster Prospects

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company, late last year, announced some preclinical test results that have the

Zacks Small Cap Research last month

NRXBF
+1.30%
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has successfully completed an important preclinical study towards its Investigational New Drug (“IND”) submission. The new study, which advances the Company’s path towards first-in-human trials, demonstrated that ExoPTEN treatment with different dose regimens led to both motor function recovery and significant impr

GlobeNewswire last month

NRXBF
+1.30%
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company") is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange ("TSXV"). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone's leadership in ...

Newsfile last month

NRXBF
+1.30%
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award

TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at MIXiii 2025, Israel’s premier Health Tech conference, organized by the Israeli Advanced Technology Industries. NurExone will participate in a special session, Innovation in Ophthalmology, showcasing cutting-edge advancements in vision-related healthcare technology. At the conference,

GlobeNewswire last month

NRXBF
+1.30%
NRXBF Pushing into US Market

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company recently announced some preclinical test results that have the

Zacks Small Cap Research 2 months ago

NRXBF
+1.30%
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock

TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“TSXV”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of ex

GlobeNewswire 2 months ago

NRXBF
+1.30%
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and gene therapy translation conference, taking place from May 7-10, 2025 in New Orleans, Louisiana, United States. As part of the Company’s growth and awareness strategy for its

GlobeNewswire 2 months ago

NRXBF
+1.30%
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization

TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“Exo-Top”), that is expected to advance good manufacturing practice (“GMP”), fully characterized exosome production. The establishment of Exo-Top is a key step towards an independent and scalable supply of high-quality exosomes for the Company’s future nanodrug pip

GlobeNewswire 2 months ago

NRXBF
+1.30%
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company”), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 856,996 units (“Units”) at a price of C$0.56 per Unit for aggregate gross proceeds of C$479,917.76 (the “Offering”). The Company intends to use t

GlobeNewswire 2 months ago

NRXBF
+1.30%
NurExone Biologic Secures Master Cell Bank

A Key Milestone for Therapeutic Exosome ProductionTORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has acquired a master cell bank from a U.S. manufacturer for an undisclosed amount (the “Acquisition”). The Acquisition marks a major step in ensuring a stable and scalable supply chain for prod

GlobeNewswire 3 months ago

NRXBF
+1.30%
NRXBF Announces Important Test Results

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN may be able to treat. On that latter point, the company recently announced some preclinical test results that have the

Zacks Small Cap Research 4 months ago

NRXBF
+1.30%
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

Paves way for additional large indications marketsTORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institut

GlobeNewswire 4 months ago

NRXBF
+1.30%
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 4 months ago

BNRG

ICON

VIOT
NRXBF: Promising Company Releases Results

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to have the opportunity to return to some

Zacks Small Cap Research 4 months ago

NRXBF
+1.30%
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and nine months ended September 30, 2024, the highlights of which are included in this news release. The Company’s complete set of condensed interim consolidated financial statements fo

GlobeNewswire 4 months ago

NRXBF
+1.30%
NRXBF Gains Another Governmental Designation

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to have the opportunity to return to some

Zacks Small Cap Research 5 months ago

NRXBF
+1.30%

Performance Overview

Return	NRXBF	S&P/TSX Composite index (^GSPTSE)
YTD	+14.42%	+0.39%
1-Year	+10.74%	+12.99%
3-Year	+113.91%	+16.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NUREXONE BIOLOGIC INC (NRXBF)

NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario

NRXBF Enters Crucial Stage in Good Shape

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

NRXBF Test Results Bolster Prospects

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock

NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award

NRXBF Pushing into US Market

NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Biologic Secures Master Cell Bank

NRXBF Announces Important Test Results

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

NRXBF: Promising Company Releases Results

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NRXBF Gains Another Governmental Designation

Performance Overview